Drew Capurro

Drew’s recent transactional experience representing companies includes:

• Mister Car Wash in its US$647 million initial public offering and subsequent US$235 million follow-on
• JOANN in its US$131 million initial public offering
• PROCEPT BioRobotics in its US$188 million initial public offering and subsequent US$161 million follow-on offering
• Winc in its initial public offering
• Guardant Health in its US$273 million initial public offering and subsequent common stock and convertible note financings
• Virgin Galactic in its business combination transaction with a special purpose acquisition company and subsequent common stock and convertible debt offerings
• Ouster in its business combination transaction with a special purpose acquisition company and subsequent financing transactions and merger of equals with Velodyne
• Offerpad in its business combination transaction with a special purpose acquisition company and subsequent equity financings
• Owlet in its business combination transaction with a special purpose acquisition company and subsequent preferred stock financing
• SciPlay in its US$352 million IPO
• Switch in its US$611 million IPO
• Boxed in its business combination transaction with a special purpose acquisition company and subsequent liquidity management transaction
• Planet Labs in its business combination transaction with a special purpose acquisition company
• GCM Grosvenor in its business combination transaction with a special purpose acquisition company
• Advantage Solutions in its business combination transaction with a special purpose acquisition company
• Virgin Orbit in its business combination transaction with a special purpose acquisition company
• MultiSensor AI, a provider of intelligent thermal imaging platforms, in its business combination with a special purpose acquisition company.
• AEON Biopharma, a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, in its business combination with a special purpose acquisition company

Drew also regularly advises private and public companies at all stages of maturity in strategic matters involving corporate governance, state and federal securities laws, fiduciary duties, employment and compensation, and Securities Exchange Act compliance and disclosure obligations.

Drew’s recent transactional experience representing investment banks includes:

• The underwriters in connection with the US$143 million IPO of Vir Biotechnology, Inc., and its US$345 million follow-on offering
• The underwriters in connection with the US$90 million IPO of Spruce Biosciences, Inc.
• The underwriters in connection with the US$70 million IPO of Avedro, Inc.
• The underwriters in connection with the US$107.5 million IPO of Neuronetics, Inc.
• The initial purchasers in connection with US$600 million convertible note offering by BioMarin
• The initial purchasers in connection with US$287.5 million convertible note offering by Glaukos

Recent clients among underwriters include Goldman Sachs, J.P. Morgan, Bank of America, Piper Jaffray, and Cowen.